ライフサイエンスコーパス: erythromycin

1 e synergistic effects of our inhibitors with erythromycin.

2 hway for the widely used antibacterial agent erythromycin.

3 codon and is de-repressed by the presence of erythromycin.

4 a molecule that kills other bacteria, i.e., erythromycin.

5 group with the exception of tetracycline and erythromycin.

6 sistance pattern of the VGS to penicillin or erythromycin.

7 e of the broad spectrum macrolide antibiotic erythromycin.

8 droxyl-containing antibiotic glycoconjugate, erythromycin.

9 re >4 g/ml, and 10 strains were resistant to erythromycin.

10 yzed) hydrolysis in the body to yield active erythromycin.

11 cherichia coli susceptible to the antibiotic erythromycin.

12 ed resistance when exposed to 0.25 microg/ml erythromycin.

13 tentiation of the activity of novobiocin and erythromycin.

14 o penicillin and fluoroquinolones but not to erythromycin.

15 omplexes in the OM decreases permeability to erythromycin.

16 eneration macrolide antibiotic prepared from erythromycin (1) and used clinically since 2004.

17 vasive isolates (36%) were nonsusceptible to erythromycin, 19 isolates (43%) were nonsusceptible to t

18 On consecutive days, erythromycin (200 mg in 20 mL 0.9% saline) or placebo (2

19 randomization, the subjects received either erythromycin 250 mg or neomycin 1 g orally QID until hos

20 for ciprofloxacin (4 mug/mL from 1 mug/mL), erythromycin (256 mug/mL from 4 mug/mL), and penicillin

21 A trend to slower transit was observed after erythromycin [300 (39-360) compared with 228 (33-360) mi

22 esistance to tetracycline (58.2%, 53/91) and erythromycin (38.5%, 35/91), whereas in S. aureus the re

23 Erythromycin (39.5%) and clindamycin (26.4%) resistance

24 239 patients received erythromycin, 410 patients received domperidone.

25 ythromycin or no co-amoxiclav, respectively (erythromycin: 53 [3.3%] of 1611 vs 27 [1.7%] of 1562, 1.

26 d with those born to mothers who received no erythromycin (594 [38.3%] of 1551 children vs 655 [40.4%

27 sizes the macrocyclic core of the antibiotic erythromycin 6-deoxyerythronolide B.

28 ere susceptible to clindamycin, 6 percent to erythromycin, 60 percent to fluoroquinolones, 100 percen

29 than did those whose mothers had received no erythromycin (658 [42.3%] of 1554 children vs 574 [38.3%

30 nd in 91% of isolates that were resistant to erythromycin (68/75).

31 st and BMD resulted in lower concordance for erythromycin (73.9%), clindamycin (65.5%), and trimethop

32 sceptible to all antimicrobial agents except erythromycin (79.1 and 76.0% susceptibilities in the 200

33 esistance to tetracycline (53.2% resistant), erythromycin (80.8% resistant or intermediate resistant)

34 ) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%;

35 tion was >96% for all the antibiotics except erythromycin (92.1%) and clindamycin (89.5%).

36 lentine leukocidin (96.3%), and resistant to erythromycin (94.1%) and, less commonly, levofloxacin (5

37 4.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addit

38 to children as a suspension of the pro-drug erythromycin A 2'-ethyl succinate.

39 -dihydro-9-acetamido-N-desmethyl-N-isopropyl erythromycin A analogues and related derivatives was gen

40 The macrolide antibiotic erythromycin A and its semisynthetic analogues have been

41 e is much more stable than the corresponding erythromycin A ester, degrading nearly 40 times more slo

42 The antibiotic erythromycin A is generally administered to children as

43 epithelial cells, effects of doxycycline and erythromycin A on inducible NO synthase (iNOS) NO produc

44 vel antibiotic that not only is as potent as erythromycin A with respect to its ability to inhibit ba

45 cursor-directed biosynthesis of 15-propargyl erythromycin A, a novel antibiotic that not only is as p

46 ndustrial-scale production of the antibiotic erythromycin A, derivatives of which play a vital role i

47 Three polyketide natural products, namely erythromycin A, lasalocid A, and iso-lasalocid A, were s

48 g the acid-catalyzed degradation reaction of erythromycin A.

49 zed hydrolysis of the 2'-ethyl succinates of erythromycins A and B.

50 l drugs--norfloxacin, a fluoroquinolone, and erythromycin, a macrolide--proteins with single mutation

51 Erythromycin, a non-peptide motilin receptor agonist, in

52 At 0.5 microg/ml erythromycin, a total of eight strains (four Campylobact

53 general anesthesia for emergency procedures, erythromycin administration increased the proportion wit

54 Last, the effect of erythromycin administration on food intake was examined

55 clinical symptoms of constipation following erythromycin administration, but the effect on colon mot

56 both G2099A and wild-type subunits, but the erythromycin affinity increases by more than 10(4)-fold,

57 lebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1.

58 penicillin, streptomycin, tetracycline, and erythromycin, among others.

59 Saccharopolyspora erythraea makes erythromycin, an antibiotic commonly used in human medic

60 this murine study, topical application of 2% erythromycin and 3% tetracycline preparations that are a

61 eater frequency of gastric contractions with erythromycin and a reduced frequency of gastric contract

62 apparently increasing its affinity for both erythromycin and ATP.

63 inical isolates with increased resistance to erythromycin and azithromycin frequently harbour mutatio

64 our structures of the macrolide antibiotics erythromycin and azithromycin in complex with a bacteria

65 ecies were also resistant to clindamycin and erythromycin and carried the erm(A) (S. pseudoporcinus)

66 ion limits in environmental risk assessment, erythromycin and ciprofloxacin were estimated to inhibit

67 were acquired locally and were resistant to erythromycin and ciprofloxacin.

68 s collaborative study assessed two different erythromycin and clindamycin concentration combinations

69 a disk approximation test (D-zone test) with erythromycin and clindamycin disks and a single-well bro

70 disks and a single-well broth test combining erythromycin and clindamycin for detection of inducible

71 single-well microdilution test incorporating erythromycin and clindamycin in combination is a sensiti

72 ancomycin, but 32% and 15% were resistant to erythromycin and clindamycin, respectively.

73 ll antibiotic classes tested or resistant to erythromycin and clindamycin.

74 SA and SpeC, and resistance to tetracycline, erythromycin and clindamycin.

75 The remaining two antibiotics (erythromycin and doxycycline) showed some intermediates

76 s chloroplast protein synthesis sensitive to erythromycin and exposure to cold.

77 ontrauma, the association between receipt of erythromycin and having a clear stomach (adjusted odds r

78 ide occurs in the presence of the antibiotic erythromycin and leads to induction of expression of the

79 BldD concurrently regulates the synthesis of erythromycin and morphological differentiation.

80 sensors that respond to acrylate, glucarate, erythromycin and naringenin.

81 Erythromycin and oleandomycin, when bound to OleD and Ol

82 mal proteins L4 and L22 confer resistance to erythromycin and other macrolide antibiotics in a variet

83 are responsible for the biosynthesis of the erythromycin and pikromycin 14-membered ring aglycones,

84 n) AUC in the colon during the fasting, post-erythromycin and postprandial phases of the study was 2.

85 ed organisms, including antibiotics, such as erythromycin and rifamycins.

86 gG expression alone allowed translocation of erythromycin and small periplasmic proteins across the o

87 . that confers resistance to the antibiotics erythromycin and tetracycline (Tc).

88 ddition to carrying resistance genes to both erythromycin and tetracycline, CTnDOT carries a gene tha

89 nt antibiotics - isoniazid, chloramphenicol, erythromycin and tetracycline.

90 tal structure of the MphR(A) protein free of erythromycin and that of the MphR(A) protein with bound

91 The ORACLE II trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxicla

92 The ORACLE I trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxicla

93 creened, 117 were randomized (58 placebo, 59 erythromycin), and 107 (91.5%) completed the study.

94 High levels of tetracycline, multidrug, erythromycin, and aminoglycoside resistance genes were d

95 Resistance to tetracycline, erythromycin, and clindamycin was seen in 11% (n = 8), 5

96 NCTC1 was resistant to penicillin and erythromycin, and contained a complement of chromosomal

97 jority of isolates (92.4%) were resistant to erythromycin, and high clindamycin resistance rates were

98 sual sugar found on the macrolide antibiotic erythromycin, and it has been shown to play a critical r

99 y were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pneumoniae and f

100 , erythromycin, clindamycin, penicillin plus erythromycin, and multiple drugs (>/=3 antibiotics) was

101 and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectively.

102 0 through 2001, occurred with ciprofloxacin, erythromycin, and penicillin.

103 acceleration of gastric emptying induced by erythromycin, and retardation of gastric motility caused

104 We identified 12 erythromycin- and clindamycin-resistant emm 90 group A s

105 (89%) were clonally related, tetracycline-, erythromycin-, and clindamycin-resistant sequence type 4

106 d to sequence type (ST)459, a tetracycline-, erythromycin-, and clindamycin-resistant ST first identi

107 tions for injectable penicillin and for oral erythromycin are downgraded.

108 comycin (Vancocin), daptomycin (Cubicin) and erythromycin) are now tractable by molecular engineering

109 bservations have implications for the use of erythromycin as a gastrokinetic drug in the critically i

110 Our aim was to evaluate the efficacy of erythromycin as an HE treatment.

111 n and that of the MphR(A) protein with bound erythromycin at 2.00- and 1.76-A resolutions, respective

112 Erythromycin, avermectin and rapamycin are clinically us

113 High MICs for erythromycin, azithromycin, and clindamycin, and interme

114 We conclude that erythromycin B 2'-ethyl succinate is an attractive prosp

115 -catalyzed degradation in solution; however, erythromycin B 2'-ethyl succinate is much more stable th

116 Thus, erythromycin B enol ether ethyl succinate is very poorly

117 ion of the unacceptably bitter taste of free erythromycin, (b) its stability against stomach acid, an

118 Macrolide antibiotics, exemplified by erythromycin, bind the 50S subunit with nM affinity and

119 Purified L22 Lys90Trp ribosomes show reduced erythromycin binding but have the same affinity for tylo

120 Erythromycin binds to OleD and the 23S RNA of its target

121 six different modules of the PKS involved in erythromycin biosynthesis (6-deoxyerythronolide B syntha

122 Unusually, the erythromycin biosynthetic (ery) cluster lacks a pathway-

123 EBS2, and DEBS3, which are housed within the erythromycin biosynthetic gene cluster.

124 robing and molecular dynamics simulations of erythromycin-bound ribosomes showed that the antibiotic

125 emic toxins on CYP3A4 activity using the 14C-erythromycin breath test and the traditional phenotypic

126 The erythromycin breath test was evaluated to determine hepa

127 s one such allele that confers resistance to erythromycin but not to tylosin and spiramycin.

128 A isolates were resistant to clindamycin and erythromycin, but CA-MRSA was more susceptible to sulfam

129 Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P

130 compared nonsusceptibility to penicillin and erythromycin by geography after standardizing difference

131 nated by organisms other than P. aeruginosa, erythromycin caused a significant change in microbiota c

132 Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess

133 MICs of erythromycin, clarithromycin, azithromycin, rifampin, ge

134 significantly more likely to be sensitive to erythromycin, clindamycin, and ciprofloxacin.

135 In general, resistance rates to erythromycin, clindamycin, and levofloxacin were higher

136 Tetracycline, erythromycin, clindamycin, and metronidazole revealed po

137 of pneumococci nonsusceptible to penicillin, erythromycin, clindamycin, penicillin plus erythromycin,

138 ch of the colonizing isolates to penicillin, erythromycin, clindamycin, tetracycline, and other antim

139 timicrobial agents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin,

140 ed an agar disk diffusion D-zone test and an erythromycin-clindamycin (ERY + CLI) single-well broth t

141 This study assessed an erythromycin-clindamycin (ERY-CC) broth test for inducib

142 Erythromycin combines the antimicrobial effect and proki

143 Median gastric transit time was lower after erythromycin compared to domperidone (13 min versus 22 m

144 rption [3-OMG AUC360: 105.2 (28.9-157.0) for erythromycin compared with 91.8 (51.4-147.9) mmol/L . mi

145 h non-CF bronchiectasis, the 12-month use of erythromycin compared with placebo resulted in a modest

146 rescription of co-amoxiclav, with or without erythromycin, compared with those born to mothers who re

147 m each genus that were not selected at lower erythromycin concentrations.

148 ates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatmen

149 eplacing the natural C12 methyl group in the erythromycin core with a vinyl group via chemical synthe

150 hesis of the clinically important antibiotic erythromycin D, the glycosyltransferase (GT) EryCIII, in

151 a cryo-electron microscopy structure of the erythromycin-dependent ErmBL-SRC.

152 yo-electron microscopy (EM) structure of the erythromycin-dependent ErmCL-stalled ribosome at 3.9 A r

153 A novel series of C12 vinyl erythromycin derivatives have been discovered which exhi

154 -substituted 2'-O,3'-N-carbonimidoyl bridged erythromycin-derived 14- and 15-membered macrolides.

155 fection dominated by Pseudomonas aeruginosa, erythromycin did not change microbiota composition signi

156 ents without P. aeruginosa airway infection, erythromycin did not significantly reduce exacerbations

157 Addition of erythromycin (Em) to a Bacillus subtilis strain carrying

158 A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by

159 Bacteroides spp. that confers resistance to erythromycin [erm(F)] and tetracycline [tet(Q)].

160 stigated the ability of four combinations of erythromycin (ERY) and clindamycin (CC) (ERY and CC at 4

161 An erythromycin (ERY) detection method is proposed using th

162 In contrast, the substrate erythromycin (ERY) had no effect on TNS lifetime, while

163 (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezoli

164 ptococcus pneumoniae isolates are macrolide (erythromycin [ERY]) resistant (ERSP), most commonly due

165 ained not just in TraB proteins, but also in erythromycin esterase (Pfam ID: PF05139), DUF399 (domain

166 ind, placebo-controlled trial of twice-daily erythromycin ethylsuccinate (400 mg) in adult patients w

167 Twice-daily erythromycin ethylsuccinate (400 mg) or matching placebo

168 lptE14 mutation increased OM permeability to erythromycin, even when the wild-type lptE gene was pres

169 train of S. erythraea with a higher titer of erythromycin expressed more BldD than a wild-type strain

170 The prescription of erythromycin for women in spontaneous preterm labour wit

171 showing resistance only to beta-lactams and erythromycin (for isolates not available for pulsed-fiel

172 Erythromycin given 30 min prior to endoscopic evaluation

173 ission, the groups were homogeneous, but the erythromycin group subjects achieved a shorter hospitali

174 ients, 42 in the placebo group and 44 in the erythromycin group.

175 clofenac, codeine, ampicillin, tetracycline, erythromycin-H2O, and gemfibrozil have significant pollu

176 Patients receiving erythromycin had nausea (20 [30%] vs 4 [6%]) and stomach

177 Co-amoxiclav (with or without erythromycin) had no effect on the proportion of childre

178 However, erythromycin has been reported to increase the prevalenc

179 Erythromycin has strong gastric prokinetic properties.

180 e, norfloxacin, ofloxacin, tetracycline, and erythromycin) have been detected through chemical analys

181 We found resistance to erythromycin in 36% of the strains, and 33% were constit

182 ), double-blind, placebo-controlled trial of erythromycin in currently nonsmoking, adult patients wit

183 Trp ribosomes bind tylosin more readily than erythromycin in vivo.

184 Resistance to erythromycin increased markedly from 2.5% in 1991 to 15%

185 Erythromycin increased small intestinal glucose absorpti

186 Erythromycin increased the proportion of macrolide-resis

187 Acute administration of erythromycin increases small intestinal glucose absorpti

188 tructures illustrates the molecular basis of erythromycin-induced gene expression and provides a fram

189 examine inducible clindamycin resistance by erythromycin induction on both CA and hospital-associate

190 The gastrokinetic drug erythromycin is commonly administered to critically ill

191 , the macrocyclic aglycone of the antibiotic erythromycin, is synthesized by a polyketide synthase (P

192 ts were administered in random order saline, erythromycin IV 150 mg, or morphine IV 0.05 mg/kg BW.

193 Erythromycin lacks colon prokinetic effect in children w

194 manometry to study the effect of intravenous erythromycin lactobionate at 1 mg/kg on colon motility i

195 Patients were randomized to intravenous erythromycin lactobionate, 3 mg/kg, or placebo 15 minute

196 lly important macrolide antibiotics, such as erythromycin, leading to the induction of the downstream

197 tance than SCCmec-IV strains to clindamycin, erythromycin, levofloxacin, gentamicin, rifampin, minocy

198 ple resistance to clindamycin, tetracycline, erythromycin, levofloxacin, or mupirocin was detected in

199 At 0.1 microg/ml erythromycin, macrolide-resistant mutants were induced i

200 Macrolide antibiotics such as erythromycin may improve clinical outcomes in non-cystic

201 -AP) and testosterone (TST) molecules to the erythromycin-metabolizing bacterial P450(eryF).

202 re prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed a

203 clindamycin of >0.25 mug/ml, 44% had MICs to erythromycin of >0.25 mug/ml, and 16% had MICs to levofl

204 We quantified the effect of erythromycin on colon contraction by calculating the are

205 e was to evaluate the effects of intravenous erythromycin on small intestinal nutrient absorption and

206 concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly

207 voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; o

208 er, more children whose mothers had received erythromycin or co-amoxiclav developed cerebral palsy th

209 e other two are induced upon incubation with erythromycin or ethidium bromide.

210 an did those born to mothers who received no erythromycin or no co-amoxiclav, respectively (erythromy

211 vel of mercury-, tetracycline-, ampicillin-, erythromycin-, or chloramphenicol-resistant oral and uri

212 eceiving placebo and 6 (3-7) in 16 receiving erythromycin (P = .002).

213 halothin (P<0.0001), clindamycin (P = 0.04), erythromycin (P<0.0001), methicillin/oxacillin (P<0.0001

214 PKS genes from the pikromycin and erythromycin pathways were hybridized in Saccharomyces c

215 We examined the effects of erythromycin, penicillin, and virginiamycin at low conce

216 r protein docking site in the context of the erythromycin PKS resulted in decreased production of the

217 main, isolated from the fourth module of the erythromycin PKS, is presented at 1.85 A resolution.

218 The sensitivity of the erythromycin plus clindamycin combination of 1 mug/ml +

219 ons in single wells (1 mug/ml + 0.25 mug/ml [erythromycin plus clindamycin] and 1 mug/ml + 0.5 mug/ml

220 PKS resulted in decreased production of the erythromycin precursor 6-deoxyerythronolide B.

221 osphopantetheinylation of ACP domains of the erythromycin precursor polyketide synthase, 6-deoxyeryth

222 lyze if a single dose of orally administered erythromycin prior to capsule endoscopy results in a hig

223 ate is an attractive prospect as a pediatric erythromycin pro-drug.

224 compounds such as chloroquine, haloperidol, erythromycin, procainamide, and ofloxacin known to activ

225 lide B (the cyclized polyketide precursor to erythromycin) production in three common heterologous ho

226 rogen peroxide (H(2)O(2)) and an antibiotic (erythromycin) recognized by the MtrC-MtrD-MtrE efflux pu

227 Erythromycin reduced 24-hour sputum production (median d

228 Compared with placebo, erythromycin reduced the rate of pulmonary exacerbations

229 in [strA-strB], chloramphenicol [cat-1], and erythromycin resistance [mefA].

230 genes was insertionally inactivated with an erythromycin resistance cassette, and the mutants were a

231 cteroides conjugative transposon, carries an erythromycin resistance gene, ermB, and previously has b

232 For isolates from human hosts, erythromycin resistance genes appeared to be associated

233 Inducible expression of the erm erythromycin resistance genes relies on drug-dependent r

234 orferi from a resident plasmid containing an erythromycin resistance marker, and this strain is then

235 only when the antibiotic is present and the erythromycin resistance methyltransferase activity is cr

236 Here we show that erythromycin resistance methyltransferase expression red

237 interactions of the nascent peptide with the erythromycin resistance methyltransferase-modified ribos

238 nucleotide in the large ribosomal subunit by erythromycin resistance methyltransferases.

239 rimoxazole resistance occurred in 239 (66%), erythromycin resistance occurred in 132 (37%), and chlor

240 Beta-hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindam

241 The mutation conferring erythromycin resistance resulted from substitution of a

242 Erythromycin resistance was high at baseline and remaine

243 Erythromycin resistance was high for staphylococci (30.6

244 ylococcus pseudintermedius isolates that are erythromycin resistant but clindamycin susceptible by in

245 ted species accounted for almost half of the erythromycin resistant enterococci isolated from the wet

246 A total of 8.8% of the isolates were erythromycin resistant, and 6.9% were clindamycin resist

247 ssembly and function, we isolated additional erythromycin-resistant E. coli mutants.

248 s recently been reported that ribosomes from erythromycin-resistant Escherichia coli strains, when is

249 -associated (HA) clindamycin-susceptible and erythromycin-resistant isolates.

250 aries and selected the mutagenized cells for erythromycin-resistant mutants.

251 coccus pyogenes isolates from an outbreak of erythromycin-resistant pharyngitis in Pittsburgh, PA, we

252 ed activity against penicillin-resistant and erythromycin-resistant pneumococci.

253 leandomycin and diverse macrolides including erythromycin, respectively.

254 been linked to the presence of a functional erythromycin ribosomal methylase (erm) gene in most spec

255 lar chimeric PKSs harboring modules from the erythromycin, rifamycin, and rapamycin synthases.

256 pared with 53 of 66 patients (80%) receiving erythromycin (risk ratio, 1.26 [95% CI, 1.01-1.57]).

257 eous IS1 insertion in secA suppressed lptE14 erythromycin sensitivity by removing the C-terminal SecB

258 Erythromycin significantly reduced PDPEs both overall (m

259 Administering erythromycin significantly stimulated food intake compar

260 enrofloxacin, tetracycline, oxytetracycline, erythromycin, spinosad, cyclo-1,3,5,7-tetramethylene tet

261 pitalization and previous abdominal surgery, erythromycin still resulted in an increased completion r

262 Moreover, erythromycin stimulated food intake, suggesting a physio

263 Tetracycline, erythromycin, sulfonamide, and ciprofloxacin resistance

264 SMEG_3312 and MSMEG_6212 are associated with erythromycin susceptibility.

265 membrane destabilization resulting in better erythromycin synergies.

266 nal DH domains, EryDH4, from module 4 of the erythromycin synthase, and NanDH2 from module 2 of the n

267 sed more BldD than a wild-type strain during erythromycin synthesis.

268 n resistance rate estimates with penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethox

269 GET was significantly faster after erythromycin than either saline or morphine.

270 t, the cecal completion rate was higher with erythromycin than with domperidone, but there was no dif

271 e and week 48 was significantly greater with erythromycin than with placebo (median Bray-Curtis score

272 ally resistant to penicillin, oxacillin, and erythromycin (the latter mediated by msrA) and carries S

273 four major classes, including the macrolide erythromycin, the ketolide telithromycin, the lincosamid

274 s aureus is suppressed by chloramphenicol or erythromycin, the susceptibility of the bacteria to cath

275 letion of bldD in S. erythraea decreased the erythromycin titer in a liquid culture 7-fold and blocke

276 the ability of the motilin receptor agonist erythromycin to induce food intake.

277 es are warranted to confirm the potential of erythromycin to reduce the incidence of bronchoaspiratio

278 nctionality, the conversion of the ketone of erythromycin to the -N(Me)CH2- group in azithromycin lea

279 reases (E-4031, d-sotalol, thioridazine, and erythromycin) to little or no effect (haloperidol, moxif

280 aimed to assess whether long-term, low-dose erythromycin treatment changes the composition of respir

281 Long-term erythromycin treatment changes the composition of respir

282 The cecal completion rate was 86% after erythromycin versus 80% after domperidone (p = 0.03).

283 One patient receiving erythromycin vomited before induction of anesthesia.

284 The number needed to harm with erythromycin was 64 (95% CI 37-209) and with co-amoxicla

285 scription of a statin with clarithromycin or erythromycin was associated with a higher risk for hospi

286 In the sample evaluated erythromycin was associated with significant reductions

287 Resistance of VGS to penicillin and erythromycin was determined by the epsilometer test.

288 Resistance to tetracycline and erythromycin was more common among human (84.6% and 26.9

289 Erythromycin was particularly efficacious in the nontrau

290 ibiotics cefepime, ampicillin, amikacin, and erythromycin was proposed.

291 The AUC following erythromycin was significantly less compared to the fast

292 S. aureus the resistance to tetracycline and erythromycin were 55.2% (16/29) and 31.0% (9/29) respect

293 MICs for penicillin and erythromycin were correlated (P <0.05).

294 ional inhibitors rifampin, tetracycline, and erythromycin were found to be ineffective in preventing

295 Lomefloxacin and erythromycin were found to be the most potent compounds

296 eptible to chloramphenicol, clindamycin, and erythromycin were lower in 2003 and 2004 than in 2001 an

297 adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4

298 dex) between baseline and week 48, comparing erythromycin with placebo.

299 functional impairment after prescription of erythromycin, with or without co-amoxiclav, compared wit

300 f children whose mothers had been prescribed erythromycin, with or without co-amoxiclav, had any func